A new injectable nanoparticle, which looks like a toothpaste gel, can be infused in the body to constantly monitor the sugar levels in the body. The nano-gel was developed at Massachusetts Institute of Technology (MIT) and may help the type 1 diabetic patients to constantly monitor their blood-sugar levels.
The nanoparticles help in sensing the glucose levels in the body; it then secretes the required amount of insulin in the body and acts exactly as pancreatic islet cells that are normally destroyed in the people with diabetes. This system can balance the blood-sugar levels in the body and improves the patients’ quality of life.
Normally, the patients with blood sugar prick their fingers several times a day to check the blood sugar levels and when their sugar levels are high they inject themselves with insulin. But the problem is the patients don't know the exact amount that is needed by the body and they end up injecting lesser amount or greater amount of insulin. This new system of extended release by injectable nanogels will help in secreting the required amount of drug needed by the body.
This new injectable gel looks like toothpaste; the gel consists of a mixture of oppositely charged nanoparticles that attract each other; this keeps the gel intact and prevents the particles from drifting away. Each nanoparticle in the gel consists of spheres of dextrin loaded with an enzyme which helps in converting glucose into gluconic acid.
The pharmacological mechanism behind this new injectable is when sugar levels are high in the body, the enzymes in the nanogel produce large quantities of gluconic acid that creates an acidic environment, and this causes the dextrin sphere to disintegrate and release insulin. The research was first conducted on mice with type 1 diabetes, and it was observed that one injection maintains the normal blood sugar level for an average of ten days.
Further research is going on this injectable nanogel to respond even more quickly to the high sugar levels. They want this nanogel to act as pancreas islet cells. The researchers are planning to further prove this delivery system, before testing the particles in humans, reported Mumbai Mirror.